Screening of Investigational Compounds to Treat, Modify or Prevent Epilepsy for the NINDS Epilepsy Therapy Screening Program (ETSP)

This pre-solicitation notice announces the National Institute of Neurological Disorders and Stroke's intent to solicit proposals for its Epilepsy Therapy Screening Program. The National Institutes of Health National Institute on Drug Abuse will award a single contract to conduct screening of investigational compounds to treat, modify or prevent epilepsy through established acute and chronic animal seizure models. The base period of performance is nine months with four one-year option periods and a three-month transition period, for a potential total of five years. The contractor will be required to screen compounds for drug resistant epilepsy, disease prevention and modification, as well as conduct ancillary and optional studies to support evolving program needs. The full RFP will be issued on or around November 2021 and proposals will be evaluated based on technical approach and price.

There is no set-aside designated for this procurement. The primary NAICS code is 541715 and PSC code is R425. The incumbent contractor is unknown. The anticipated value is unknown but the contractor will be required to screen numerous investigational compounds over the five-year period of performance using established animal models and study workflows to support the National Institute of Neurological Disorders and Stroke's efforts to develop new epilepsy therapies.